Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Kazem Rahimi

Kazem Rahimi

Kazem Rahimi

Lead Researcher, Deep Medicine Programme

  • Associate Professor of Cardiovascular Medicine
  • James Martin Senior Fellow in Essential Healthcare at the University of Oxford
  • Honorary Consultant Cardiologist at the John Radcliffe Hospital, Oxford

Prof Kazem Rahimi is a cardiologist with research interests in the area of clinical trials and health services research.

Kazem leads the Healthcare Innovation and Evaluation programme, which aims to find practical and affordable solutions for the global health priorities of the world¹s largest emerging economies, as well as the priorities of vulnerable or disadvantaged populations in established economies.

Kazem graduated in medicine from the University of Leipzig in Germany with postgraduate training in cardiology, epidemiology, clinical trials and health services research in Leipzig, London and Oxford. Prior to joining the George Institute, in 2010, he was a Research Fellow at Oxford’s Clinical Trial Service and Epidemiological Studies Unit. His research interests include hypertension, heart failure and cardiovascular risk management, using a variety of methodologies such as individual-patient meta-analysis, large-scale complex intervention trials, and digital health technologies.

Kazem is currently the Chief Investigator of several large-scale projects and programmes including the SUPPORT-HF (a trial of remote self-management support in patients with heart failure), UNVEIL-CHF (a programme of research into variation in management of heart failure patients using large clinical datasets), BPLTTC (an international collaboration of blood pressure lowering trialists) and the SUPPORT-CVD trial (a large-scale cluster RCT of risk-stratified prevention and management of CVD with the use of low-cost technologies including the cardiovascular polypill).